Guadeloupe – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 04:16:49 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Guadeloupe – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Comparing the timing of etoposide and dexamethasone treatment for patients with severe sporadic hemophagocytic lymphohistiocytosis in intensive care. https://clinicaltrials.eu/trial/comparing-the-timing-of-etoposide-and-dexamethasone-treatment-for-patients-with-severe-sporadic-hemophagocytic-lymphohistiocytosis-in-intensive-care/ Wed, 29 Apr 2026 15:09:00 +0000 https://clinicaltrials.eu/trial/comparing-the-timing-of-etoposide-and-dexamethasone-treatment-for-patients-with-severe-sporadic-hemophagocytic-lymphohistiocytosis-in-intensive-care/ This study focuses on patients with Hemophagocytic lymphohistiocytosis, a rare and serious condition where the immune system becomes overactive and causes excessive inflammation. This inflammation can lead to organ failure, which occurs when vital organs like the liver, kidneys, or lungs stop working correctly. The study is being conducted to compare two different ways of starting a treatment called etoposide in patients who are receiving intensive care. All patients in the study also receive dexamethasone, a medication used to reduce inflammation.

The first group will receive etoposide very early, within 12 hours of being admitted to the study. The second group will follow a delayed strategy, where the medication is only started if the patient’s condition does not improve after 48 hours. During the course of the study, researchers will monitor how these different timing strategies affect the development or worsening of organ problems. The study will also look at various aspects of recovery, such as the length of time spent in the hospital and the need for support from machines like a ventilator, which helps a person breathe.

]]> Study on Etoposide for Patients with Severe Hemophagocytic Lymphohistiocytosis in Intensive Care https://clinicaltrials.eu/trial/study-on-etoposide-for-patients-with-severe-hemophagocytic-lymphohistiocytosis-in-intensive-care/ Wed, 29 Apr 2026 15:02:40 +0000 https://clinicaltrials.eu/trial/study-on-etoposide-for-patients-with-severe-hemophagocytic-lymphohistiocytosis-in-intensive-care/ This clinical trial is focused on studying a condition called Hemophagocytic Lymphohistiocytosis (HLH), which is a severe disorder where the body’s immune system becomes overly active and starts attacking its own tissues. The study is investigating the use of a medication called Etoposide, which is commonly used in cancer treatment, to see how it can help manage this condition when it becomes severe and requires intensive care.

The purpose of the study is to compare two different strategies for starting treatment with Etoposide in patients with severe HLH. One strategy involves starting the treatment early, within 12 hours of the patient being included in the study. The other strategy involves delaying the start of the treatment until 48 hours later, but only if the patient’s condition does not improve. This approach will help researchers understand which timing is more effective in managing the condition and preventing further organ damage.

Participants in the study will be monitored closely to see how their condition progresses with each treatment strategy. The study will look at various outcomes, such as the time it takes for symptoms to improve, the number of days patients spend on ventilators, and the overall length of their hospital stay. The study aims to provide valuable insights into the best way to use Etoposide for treating severe HLH in intensive care settings.

]]>